NCT03021174 is a NA clinical trial of EXCAP Exercise in Neuropathy;Peripheral, sponsored by University of Rochester.

Who is sponsoring NCT03021174?

NCT03021174 is sponsored by University of Rochester.

What drugs are being tested in NCT03021174?

Interventions in NCT03021174: EXCAP Exercise, Nutrition Education Control.

What condition does NCT03021174 study?

NCT03021174 studies Neuropathy;Peripheral.

Is NCT03021174 still recruiting?

NCT03021174 is currently completed. Last updated 18 July 2019.

Last reviewed 2019-07-18 · How we verify

NCT03021174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise and Nutrition Interventions During Chemotherapy

Completed NA Last updated 18 July 2019

What this trial tests

NA trial testing EXCAP Exercise in Neuropathy;Peripheral in 21 participants. Completed in 11 October 2018.

Timeline

28 June 2017

Primary endpoint
11 October 2018

11 October 2018

Quick facts

Lead sponsor	University of Rochester
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	21
Start date	28 June 2017
Primary completion	11 October 2018
Estimated completion	11 October 2018
Sites	1 location across United States

Drugs / interventions tested

EXCAP Exercise
Nutrition Education Control

Conditions studied

Neuropathy;Peripheral — all drugs for Neuropathy;Peripheral →

Sponsor

University of Rochester

Who can join

18 and older, any sex, with Neuropathy;Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a feasibility pilot study to initiate a research program to assess the effects of exercise on chemotherapy-induced peripheral neuropathy (numbness, tingling, and pain in the hands and feet).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system.
Kleckner IR, Manuweera T, Lin PJ, Chung KH, et al · · 2024 · cited 10× · PMID 39304604 · DOI 10.1007/s00520-024-08855-y
Preliminary evaluation of novel Bodily Attention Task to assess the role of the brain in chemotherapy-induced peripheral neurotoxicity (CIPN).
Manuweera T, Wagenknecht A, Kleckner AS, Dorsey SG, et al · · 2024 · cited 7× · PMID 38070689 · DOI 10.1016/j.bbr.2023.114803
Feasibility of Daily Assessments of Chemotherapy Toxicities to Predict Daily Exercise Behavior During a Home-Based Exercise Intervention.
Chung K, Wagenknecht AG, Kleckner AS, Loh KP, et al · · 2025 · cited 2× · PMID 40293932 · DOI 10.1188/25.onf.179-190
Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system
Kleckner IR, Manuweera T, Lin P, Chung KH, et al · · 2024 · DOI 10.21203/rs.3.rs-4022351/v1

Verify or expand the search:

Other trials of EXCAP Exercise

Trials testing the same drug.

NCT05452902 — Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21 · Phase 2 · terminated
NCT03858153 — Exercise and Nutrition Interventions During Chemotherapy K07 · Phase 2 · completed

Other recruiting trials for Neuropathy;Peripheral

Currently open trials in the same condition.

NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT06912646 — Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain · NA · recruiting
NCT06471517 — Neuroprosthetic Device for Improving Issues Caused by Diabetic Neuropathy With Specifically Designed Neural Stimulation · NA · recruiting
NCT05980169 — The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy · NA · active not recruiting
NCT06121232 — Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Mar · NA · active not recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03021174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 18 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03021174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing